Immune-Checkpoint Inhibitors in the Hepatitis C-Infected Patient: To Use or Not to Use?

Michele S Barnhill¹, Hugo E Vargas^{1

2}

Affiliations

¹ Transplant Center, Mayo Clinic, Phoenix, Arizona, USA.
² Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.

Editorial

Michele S Barnhill et al. Am J Gastroenterol. 2023.

. 2023 Sep 1;118(9):1554-1555.

doi: 10.14309/ajg.0000000000002352. Epub 2023 May 25.

Michele S Barnhill¹, Hugo E Vargas^{1

2}

¹ Transplant Center, Mayo Clinic, Phoenix, Arizona, USA.
² Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.

No abstract available

Comment on

Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.
Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Yibirin M, et al. Am J Gastroenterol. 2023 Sep 1;118(9):1609-1617. doi: 10.14309/ajg.0000000000002361. Epub 2023 Jun 13. Am J Gastroenterol. 2023. PMID: 37307533 Free PMC article.

1. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13(8):473–86.
1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54.
1. Alkrekshi A, Tamaskar I, Safety of immune checkpoint inhibitors in patients with cancer and hepatitis C virus infection. Oncologist 2021;26(5):e827–30.
1. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012;9:156–66.
1. Yibirin M, Mustafayev K, Hosry J, et al. Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors. Am J Gastroenterol 2023;118(9):1609-17.